# Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer

> **NCT04517838** · — · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 230 (estimated)

## Conditions studied

- Breast Adenocarcinoma
- HER2-Positive Breast Carcinoma
- Anatomic Stage I Breast Cancer AJCC v8
- Anatomic Stage II Breast Cancer AJCC v8
- Anatomic Stage III Breast Cancer AJCC v8
- Anatomic Stage IV Breast Cancer AJCC v8

## Interventions

- **PROCEDURE:** Biospecimen Collection

## Key facts

- **NCT ID:** NCT04517838
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2020-07-31
- **Primary completion:** 2028-07-27
- **Final completion:** 2028-07-27
- **Target enrollment:** 230 (ESTIMATED)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04517838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04517838, "Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04517838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*